Device and methods
AssigneeEpona Biotech Ltd
InventorsHeinrich Anhold, Ruth Candon, Di-Sien Chan
Life of this patent
Estimating the term…
Abstract
There is provided a method and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. Diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy are provided. A test fluid collection system adapted to permit dilution and analysis of the collected test fluid and an assay and device for monitoring exertional rhabdomyolysis in equines is also provided.
Claims6
A method of monitoring a mammal's response to a treatment for an infectious disease or an inflammatory response comprising administration of an anti-infective to the mammal, the method comprising:
- collecting, by an analytical device, a body fluid sample of said mammal after treatment has been administered, the analytical device including a sample well, viewing window, and a flow path through which the body fluid sample flows by capillary action, the flow path leading from the sample well to the viewing window;
- determining, by the analytical device, a concentration of Serum Amyloid A in the body fluid sample of said mammal;
- and
- producing, by the analytical device in the viewing window, a visual representation of the determined concentration of Serum Amyloid A, the visual representation indicating whether the determined concentration is above a specified level, wherein said specified level is 50 μg/ml, and wherein said body fluid is a blood sample.
A method of monitoring a mammal's response to a treatment for an infectious disease or an inflammatory response comprising administration of an anti-infective to the mammal, the method comprising:
- collecting, by an analytical device, a body fluid sample of said mammal after treatment has been administered, the analytical device including a sample well, viewing window, and a flow path through which the body fluid sample flows by capillary action, the flow path leading from the sample well to the viewing window;
- determining, by the analytical device, a concentration of Serum Amyloid A in the body fluid sample of said mammal;
- and
- producing, by the analytical device in the viewing window, a visual representation of the determined concentration of Serum Amyloid A, the visual representation indicating whether the determined concentration is above a specified level, wherein said specified level is 50 μg/ml, wherein said body fluid is a blood sample, and wherein said treatment is administered if the determined concentration of Serum Amyloid A is above 50 μg/ml and wherein said treatment is stopped if the determined concentration of Serum Amyloid A is below 50 μg/ml.
Dependencies are inferred from the claim text.